kallistatin + simvastatin

This is a combination therapy of kallistatin, a serine proteinase inhibitor with anti-inflammatory and anti-apoptotic properties, and simvastatin, an HMG-CoA reductase inhibitor (statin) used primarily to lower cholesterol. The combination has been studied for its potential synergistic effects in reducing inflammation and endothelial cell apoptosis. In pediatric burn sepsis patients, combined treatment with simvastatin and kallistatin was shown to decrease pro-inflammatory cytokines (such as TNF-α and IL-1β), increase anti-inflammatory markers (IL-10), reduce blood urea nitrogen and serum creatinine levels, downregulate Toll-like receptor 4 expression on monocytes, upregulate suppressor of cytokine signaling-3 expression, inhibit high mobility group box-1-induced NF-κB activation, promote human endothelial cell growth, and decrease apoptosis through modulation of Bcl-2 family proteins[1]. Simvastatin’s primary mechanism is inhibition of cholesterol synthesis via competitive inhibition of HMG-CoA reductase[3]. Kallistatin acts mainly by inhibiting tissue kallikrein activity but also exerts pleiotropic protective effects on vascular endothelium.